Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil for Spontaneous Hyperventilation in Severe TBI
NCT04974060Unknown
- Sponsor
- Capital Medical University
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of remifentanil in hyperventilation syndrome (HVS), sponsored by Capital Medical University. Primary endpoint: Effective and safe dose of remifentanil to correct spontaneous hyperventilation. Status: unknown.
02
Drugs
remifentanil
03
Conditions
hyperventilation syndrome (HVS)
Beyond the preview
Go deeper on NCT04974060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974060.